Welcome to CDC stacks | Bangkok Tenofovir Study : PrEP for HIV prevention among people who inject drugs - 23087 | Stephen B. Thacker CDC Library collection
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All Simple Search
Advanced Search
Bangkok Tenofovir Study : PrEP for HIV prevention among people who inject drugs
  • Published Date:
    June 2013
  • Language:
Filetype[PDF-130.52 KB]

  • Corporate Authors:
    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.)
  • Description:
    Daily oral PrEP (pre-exposure prophylaxis) with a tablet containing tenofovir disoproxil fumarate (tenofovir, marketed in the United States under the brand name Viread®) was found to reduce the risk of acquiring HIV by approximately 49 percent in a study of 2,413 men and women who inject drugs in Bangkok, Thailand. Those who took the medication consistently had higher levels of protection, similar to findings previously reported from other PrEP trials. In a separate analysis of participants known to be adherent, because they were observed taking their medication and had tenofovir detected in their blood, the risk of HIV acquisition was reduced by approximately 74 percent.

    This is the first study to report results of PrEP efficacy among people who inject drugs. Previous studies have found that PrEP with tenofovir – alone or in combination with emtricitabine (brand name Truvada®) – can reduce the risk of sexual transmission of HIV among heterosexuals and men who have sex with men.

  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like: